Moderna’s departing legal chief could make $8M from Arbutus and Pfizer patent litigation outcomes, SEC filing reveals

Context: Moderna has been embroiled in a number of high-profile patent disputes over technologies used in Covid-19 mRNA vaccines, including with key competitors Pfizer and BioNTech (February 20, 2026 ip fray article), as well as GlaxoSmithKline (November 9, 2026 ip fray article), CureVac (July 21, 2026 ip fray article)  and Arbutus Biopharma (March 4, 2026 ip fray article).

What’s new & direct impact: Moderna has made a regulatory filing with the U.S. Securities and Exchange Commission (SEC) detailing a retirement agreement it has reached with its Chief Legal Officer, Shannon Thyme Klinger. According to the filing, Ms. Klinger stands to receive payments worth up to $8 million dependant on the outcome of patent litigation Moderna is involved in with Arbutus and Pfizer.

Wider ramifications: The SEC filing gives a rare detailed glimpse into the specifics of in-house counsel compensation, and the role of contingent litigation-related payments in particular. The arrangements between Moderna and the departing Ms. Klinger could inform other retirement agreements for senior legal and IP executives.

Under the terms of the retirement agreement detailed in Moderna’s SEC filing, Ms. Klinger is expected to leave her role as Chief Legal Officer at the end of March 2027. Assuming she does so, and complies with various conditions, she will be paid just over $1.62 million in severance, based on her current salary and potential annual bonus.

Beyond that, the retirement agreement includes “Contingent Litigation Success Payments” relating to Moderna’s ongoing patent disputes with Arbutus and its partner Genevant Sciences on the one hand, and Covid-19 vaccine competitors Pfizer and BioNTech on the other.

The Arbutus-Genevant case is now pending before the U.S. Court of Appeals for the Federal Circuit, where Moderna is arguing that U.S. government contractor immunity means it needn’t pay the co-plaintiffs $1.3 billion in expanded damages for patent infringement.

Ms. Klinger’s proposed retirement agreement states:

“[I]f Moderna is the prevailing party upon the conclusion of all Arbutus Proceedings, Moderna shall make a payment to [Ms. Klinger] of $2,500,000… Moderna shall be considered to be the prevailing party only if, based upon the conclusion of the Arbutus Proceedings, it is not obligated pursuant to an order, judgment, or award of a court or arbitrator to make any payments to Arbutus Biopharma Corp, Genevant Sciences GmbH or any designee of either of the foregoing.”

Moderna also has a pending lawsuit against Pfizer and BioNTech in the U.S. District Court for the District of Massachusetts. For this case, the retirement agreement says:

[I]f Moderna secures a recovery of money or other consideration of commercial value as a result of the conclusion of all Pfizer Proceedings, including without limitation a conclusion by settlement, Moderna shall pay {Ms. Klinger] the lesser of $5,500,000 or the total amount that it recovers as a result of the Pfizer Proceedings.”

For both disputes, the agreement notes that the pending cases may be followed by further appellate, other court, or arbitration proceedings that could impact or delay any payout to Ms. Klinger.

Form 8-K